Literature DB >> 19707831

Resectable pancreatic cancer: who really benefits from resection?

Giuliano Barugola1, Stefano Partelli, Stefano Marcucci, Nora Sartori, Paola Capelli, Claudio Bassi, Paolo Pederzoli, Massimo Falconi.   

Abstract

BACKGROUND: The 1-year disease-related mortality after resection for pancreatic cancer is approximately 30%. This study examined potential preoperative parameters that would help avoid unnecessary surgery.
METHODS: Among the patients resected at our institution from 1997 to 2006, a total of 228 underwent pancreatic resection for ductal adenocarcinoma. By means of a survival cutoff of 12 months, two groups were created: early death (ED) and long survivors. A logistic regression analysis was performed to identify perioperative predictors of ED.
RESULTS: Among 228 resected patients, postoperative mortality occurred in four cases (1.8%) that were excluded from the study. In the remaining 224 patients, 43 (19.2%) died of disease within 12 months from surgery (ED), and the remaining 181 (80.8%) had a longer survival. Multivariate analysis selected duration of preoperative symptoms > 40 days, CA 19-9 > 200 U/mL, pathological grading G3-G4, and R2 resection as independent predictors of ED.
CONCLUSIONS: Duration of symptoms, CA 19-9 serum level, and pathological grading possibly retrieved by endoscopic ultrasound-guided biopsy can be preoperatively used to identify patients with disease that is not suitable for up-front surgery, even if deemed resectable by high-quality imaging.

Entities:  

Mesh:

Year:  2009        PMID: 19707831     DOI: 10.1245/s10434-009-0670-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  57 in total

1.  Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer.

Authors:  Charles C Hsu; Christopher L Wolfgang; Daniel A Laheru; Timothy M Pawlik; Michael J Swartz; Jordan M Winter; Raymond Robinson; Barish H Edil; Amol K Narang; Michael A Choti; Ralph H Hruban; John L Cameron; Richard D Schulick; Joseph M Herman
Journal:  J Gastrointest Surg       Date:  2012-02-07       Impact factor: 3.452

2.  Contrast enhanced ultrasound with quantitative perfusion analysis for objective characterization of pancreatic ductal adenocarcinoma: A feasibility study.

Authors:  Mirko D'Onofrio; Stefano Canestrini; Stefano Crosara; Riccardo De Robertis; Roberto Pozzi Mucelli
Journal:  World J Radiol       Date:  2014-03-28

3.  Current surgical management of pancreatic cancer.

Authors:  Charles B Kim; Shuja Ahmed; Eddy C Hsueh
Journal:  J Gastrointest Oncol       Date:  2011-09

4.  Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.

Authors:  Jae W Lee; Chad A Komar; Fee Bengsch; Kathleen Graham; Gregory L Beatty
Journal:  Curr Protoc Pharmacol       Date:  2016-06-01

5.  Impact of Intratumoral Inflammation on Survival After Pancreatic Cancer Resection.

Authors:  Phil A Hart; Thomas C Smyrk; William R Bamlet; Suresh T Chari
Journal:  Pancreas       Date:  2016-01       Impact factor: 3.327

6.  CPA4 is a promising diagnostic serum biomarker for pancreatic cancer.

Authors:  Lichao Sun; Joseph Burnett; Chunguang Guo; Yibin Xie; Jian Pan; Zhihua Yang; Yuliang Ran; Duxin Sun
Journal:  Am J Cancer Res       Date:  2015-12-15       Impact factor: 6.166

7.  Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre.

Authors:  Giuliano Barugola; Stefano Partelli; Stefano Crippa; Giovanni Butturini; Roberto Salvia; Nora Sartori; Claudio Bassi; Massimo Falconi; Paolo Pederzoli
Journal:  HPB (Oxford)       Date:  2013-03-12       Impact factor: 3.647

Review 8.  Indications to total pancreatectomy for positive neck margin after partial pancreatectomy: a review of a slippery ground.

Authors:  Stefano Crippa; Giulio Belfiori; Domenico Tamburrino; Stefano Partelli; Massimo Falconi
Journal:  Updates Surg       Date:  2021-07-31

9.  A novel, validated risk score to predict surgical site infection after pancreaticoduodenectomy.

Authors:  Katherine E Poruk; Joseph A Lin; Michol A Cooper; Jin He; Martin A Makary; Kenzo Hirose; John L Cameron; Timothy M Pawlik; Christopher L Wolfgang; Frederic Eckhauser; Matthew J Weiss
Journal:  HPB (Oxford)       Date:  2016-09-10       Impact factor: 3.647

10.  Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer.

Authors:  Mohammed Aldakkak; Kathleen K Christians; Ashley N Krepline; Ben George; Paul S Ritch; Beth A Erickson; Fabian M Johnston; Douglas B Evans; Susan Tsai
Journal:  HPB (Oxford)       Date:  2015-08-10       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.